Subject
Psychiatry and Mental health,Clinical Psychology
Reference71 articles.
1. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder;Alvarez;Int. J. Neuropsychopharmacol.,2012
2. Anon, 2013. Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine) for treatment of adults with major depressive disorder. Press release. 1 October 2013. Available from: 〈http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=794050〉 accessed (01.02.15).
3. Efficacy and safety of levomilnacipran sustained release 40mg, 80mg, or 120mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study;Asnis;J. Clin. Psychiatry,2013
4. Levomilnacipran ER 40mg and 80mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study;Bakish;J. Psychiatry Neurosci.,2014
5. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD);Baldwin;Eur. Neuropsychopharmacol.,2012
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献